Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some key FDA label elements are supported (indication and dosing schedule/route for IV and ORS), but multiple mechanistic/pharmacologic and efficacy claims (e.g., oxidative stress rationale; slowing functional decline) are not supported by the provided label excerpts, and several adverse reaction items are only partially supported (e.g., “common side effects” framing and ORS-specific reactions beyond contusion/headache/daphylasis).
Category Scores
Accurate Statements
Radicava (edaravone) is used to treat amyotrophic lateral sclerosis (ALS).
Section 1 — “RADICAVA and RADICAVA ORS are indicated for the treatment of amyotrophic lateral sclerosis (ALS).”
Radicava is approved for the treatment of amyotrophic lateral sclerosis (ALS) in adults.
Section 1 indicates indication for ALS; provided excerpts do not explicitly state “in adults,” but adult limitation is not contradicted by the excerpts.
The initial Radicava treatment regimen is an intravenous infusion of 60 mg over 60 minutes once a day for 14 days.
Section 2.1 — IV “60 mg administered over a 60-minute period”; initial cycle daily for 14 days.
The initial Radicava regimen includes a 14-day drug-free period after the first 14 days.
Section 2.1 — “initial treatment cycle…daily dosing for 14 days, followed by a 14-day drug-free period.”
Subsequent Radicava treatment cycles are intravenous infusions of 60 mg once a day for 10 days out of 30 days.
Section 2.1 — subsequent cycles: “daily dosing for 10 days out of 14-day periods” (not “30 days”); however the 10-days-on pattern is supported.
Subsequent Radicava cycles include 20-day drug-free periods after the 10 days of dosing.
Derived from label schedule (10 days dosing followed by 14-day drug-free periods = 14 days off, not 20); partially supported pattern but the numeric “20-day” drug-free period is not supported.
A newly approved oral formulation of Radicava (Radicava ORS) allows for daily dosing without the need for infusions.
Section 2.1/2.3 — RADICAVA ORS is taken orally or via feeding tube (105 mg) rather than infused; provided excerpts do not support “newly approved” or timeline.
Radicava ORS is an oral suspension.
Section 3 — “RADICAVA ORS is supplied as an oral suspension…105 mg/5 mL.”
Radicava ORS can be taken by mouth.
Section 2.3 — “can be administered by mouth…”
Radicava ORS can be administered through a feeding tube.
Section 2.3 — “…or via feeding tube.”
Hypersensitivity reactions have been reported with Radicava, including rash.
Section 5.1 — “Hypersensitivity reactions… and cases of anaphylaxis… have been reported…” (rash is not explicitly listed in the excerpt; label basis is general hypersensitivity reporting).
Hypersensitivity reactions have been reported with Radicava, including urticaria.
Section 5.1 — hypersensitivity reactions reported; excerpt does not explicitly list urticaria.
Hypersensitivity reactions have been reported with Radicava, including pruritus.
Section 5.1 — hypersensitivity reactions reported; excerpt does not explicitly list pruritus.
Patients receiving Radicava ORS may experience headache.
Section 6.1 — “Most common adverse reactions… contusion, gait disturbance, and headache.” (ORS-specific attribution not explicitly stated in excerpt).
Patients receiving Radicava ORS may experience contusion.
Section 6.1 — “Most common adverse reactions… contusion… and headache.” (ORS-specific attribution not explicitly stated in excerpt).
The efficacy and safety of Radicava ORS have been demonstrated in clinical trials.
Section 14 — efficacy of ORS based on bioavailability study; provided excerpts do not explicitly state “safety and efficacy demonstrated” for ORS, but clinical study basis is referenced.
Unsupported Statements
Radicava works by reducing oxidative stress.
No mechanism of action statements regarding oxidative stress are present in the supplied label excerpts.
Oxidative stress is believed to contribute to nerve cell damage seen in ALS.
No such pathophysiology/justification is included in the supplied label excerpts.
Radicava functions as a free radical scavenger.
No mechanism/free radical scavenger description is present in the supplied label excerpts.
Oxidative stress (an imbalance between free radicals and antioxidants) is implicated in the progression of ALS.
Not present in supplied label excerpts.
By neutralizing harmful free radicals, Radicava aims to protect motor neurons from damage.
Not present in supplied label excerpts.
Radicava may slow the rate of functional decline in ALS patients.
No clinical benefit statement about slowing functional decline is included in the supplied label excerpts.
Common side effects of Radicava infusions include bruising.
Label excerpt lists contusion/gait disturbance/headache; 'bruising' is not explicitly stated, though contusion is close in meaning. The provided excerpts do not explicitly equate bruising=contusion.
Common side effects of Radicava infusions include gait disturbances.
Supported as “gait disturbance” is listed; however 'gait disturbances' wording is not an explicit label phrase. Likely supported but not verbatim.
Common side effects of Radicava infusions include headache.
Supported in Section 6.1 as “headache.” (Route/formulation specific to infusion is not explicitly distinguished in excerpt.)
Patients receiving Radicava ORS may experience dermatitis.
Not present in the supplied label excerpts.
Patients receiving Radicava ORS may experience eczema.
Not present in the supplied label excerpts.
Radicava was first approved by the U.S. Food and Drug Administration (FDA) in May 2017 for the treatment of ALS.
No approval date/timeline information is present in the supplied label excerpts.
Radicava ORS received FDA approval in May 2022.
No approval date/timeline information is present in the supplied label excerpts.
Radicava is manufactured by Mitsubishi Tanabe Pharma America, Inc.
No manufacturer information is present in the supplied label excerpts.
Hypersensitivity reactions have been reported with Radicava, including rash.
Section 5.1 excerpt provided describes hypersensitivity reactions generally but does not list rash explicitly.
Hypersensitivity reactions have been reported with Radicava, including urticaria.
Section 5.1 excerpt provided describes hypersensitivity reactions generally but does not list urticaria explicitly.
Hypersensitivity reactions have been reported with Radicava, including pruritus.
Section 5.1 excerpt provided describes hypersensitivity reactions generally but does not list pruritus explicitly.
Contradictions
Low
AI Statement
Subsequent Radicava treatment cycles are intravenous infusions of 60 mg once a day for 10 days out of 30 days.
Label Reference
Section 2.1 — subsequent cycles described as “10 days out of 14-day periods,” not 30 days.
Low
AI Statement
Subsequent Radicava cycles include 20-day drug-free periods after the 10 days of dosing.
Label Reference
Section 2.1 — 10 days dosing followed by a 14-day drug-free period; not 20 days.
Important Omissions
For RADICAVA ORS, the label includes meal/fasting timing (morning after overnight fasting; avoid food for 1 hour after administration except water).
Importance:
Moderate
For RADICAVA IV, the label includes administration detail that each 60 mg dose is given as two consecutive 30 mg infusion bags over a total of 60 minutes (and that RADICAVA is for intravenous infusion only).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Primary safety-critical mismatch relates to incorrect cycle timing ('10 days out of 30 days' and '20-day drug-free periods' vs label '10 days out of 14-day periods' and '14-day drug-free periods'). Other claims are largely mechanistic/benefit statements not supported by excerpts, and adverse reaction lists for ORS (dermatitis/eczema) are not supported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Incorrect subsequent dosing cycle duration/drug-free period (30-day framing and 20-day drug-free period) and multiple unsupported mechanistic/benefit and ORS adverse reaction claims.
Suggested Improvement
Use the label’s exact subsequent cycle schedule: daily dosing for 10 days out of each 14-day period followed by a 14-day drug-free period; remove or qualify unsupported oxidative stress/free radical mechanism and functional decline claims; restrict adverse reaction statements for ORS to items explicitly supported by the provided label excerpts (e.g., headache/contusion as listed) and avoid unsupported dermatitis/eczema claims; for ORS, include fasting/food restriction after dosing and for IV include the two 30 mg bag infusion administration detail.